InVivo Therapeutics Holdings Net Total Equity Issued/Repurchased 2010-2023 | NVIVQ
InVivo Therapeutics Holdings net total equity issued/repurchased from 2010 to 2023. Net total equity issued/repurchased can be defined as the sum of all preferred and common equity transactions regarding a company's own stock.
| InVivo Therapeutics Holdings Annual Net Total Equity Issued/Repurchased (Millions of US $) |
|
|---|---|
| 2022 | $8 |
| 2021 | $9 |
| 2020 | $22 |
| 2019 | $0 |
| 2018 | $17 |
| 2017 | $0 |
| 2016 | $30 |
| 2015 | $23 |
| 2014 | $15 |
| 2013 | $16 |
| 2012 | $19 |
| 2011 | $3 |
| 2010 | $11 |
| 2009 | $N/A |
| 2009 | $N/A |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED PRODUCTS | $0.000B | $0.000B |
| InVivo Therapeutics Holdings Corp. operates as a medical device company focused on utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed as a result of traumatic spinal cord injury. The company intends to offer three products, including a biocompatible polymer scaffolding device to treat acute wound SCI; a biocompatible hydrogel for local controlled release of methylprednisolone to treat acute SCI; and a biocompatible polymer scaffolding device seeded with autologous hNSCs to treat acute and chronic SCI. InVivo Therapeutics Holdings Corp. is based in Cambridge, Massachusetts. | |||